NCT07511829 WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment
| NCT ID | NCT07511829 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oxford |
| Condition | MDS (Myelodysplastic Syndrome) |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-02-17 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2026-02-17 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia. This can cause severe fatigue, shortness of breath and brain fog and may need regular blood transfusions. Their quality of life (QoL) is often very poor during treatment because of these side effects, and it is hard to deal with. Doctors use blood tests to decide whether a patient is well enough for treatment and when to start treatment. However, blood tests do not tell us how a person feels, and it is not the same in everyone. We need a better way for doctors to monitor patients' QoL and these symptoms so that they are physically and emotionally able to continue their treatment. It is hard for doctors to accurately assess this through speaking to their patients and doctors do not record or discuss these effects of treatment very well with patients. The aim of this study is to better understand how people feel during their treatment and how we can best use blood transfusions to maintain QoL. 80 adult patients who are starting blood cancer treatments will be asked to answer questionnaires about how they are feeling and their symptoms during their treatment. Participants will be asked to wear a smartwatch to measure their physical activity levels. Activity data collected will then be compared with their reported QoL and blood counts to help us understand when patients can tolerate difficult treatments the best and how blood transfusions affect this. Patients, their family and carers will be invited to take part in an interview to understand their views on how we can improve their care, QoL and access to transfusions. A better understanding of the impact of low blood counts on QoL can help us use blood transfusions to benefit patients' lives. This work will better match transfusions to individual peoples' needs and therefore 'personalise' blood transfusion care.
Eligibility Criteria
Inclusion Criteria: * Patients aged ≥18 years with WHO-defined MDS or mixed myeloproliferative/myelodysplastic neoplasm overlap syndromes (MPN/MDS), myeloma and AML * Intention to undertake disease modifying treatment * Life expectancy ≥ 6 months * Able to complete quality of life questionnaires * Willing and able to provide informed consent for participation in the study * Willing to receive blood products as part of normal NHS care Exclusion Criteria: * Poor performance/functional status (Eastern Cooperative Oncology Group system ECOG ≥3) * Participants with known arrhythmias or other significant cardiological conductivity disorders * Patients with severe comorbidities * Patients with known skin allergies or conditions that in the opinion of the investigator would compromise the safety of the patient or quality of the data * Hospitalised patients * Patients currently participating in another interventional clinical study * Patients with a pacemaker or implanted cardioverter defibrillator or any cardiac implanted device
Contact & Investigator
Matthew H Poynton, MBBS
PRINCIPAL INVESTIGATOR
University of Oxford
Frequently Asked Questions
Who can join the NCT07511829 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying MDS (Myelodysplastic Syndrome). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07511829 currently recruiting?
Yes, NCT07511829 is actively recruiting participants. Contact the research team at matthew.poynton@linacre.ox.ac.uk for enrollment information.
Where is the NCT07511829 trial being conducted?
This trial is being conducted at Oxford, United Kingdom.
Who is sponsoring the NCT07511829 clinical trial?
NCT07511829 is sponsored by University of Oxford. The principal investigator is Matthew H Poynton, MBBS at University of Oxford. The trial plans to enroll 80 participants.